This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Chief Financial Officer
Mr. Levy has over 15 years of experience in finance and administration.
Prior to joining BrainsWay, Mr. Levy served as a finance manager in the Latin America Division at Amdocs Ltd., where he was responsible for accounting, financial reporting, treasury, portfolio management and finance support for Mergers & Acquisitions.
Prior to Amdocs, he served as Chief Financial Officer & Business Development of Notal Vision, a healthcare company that researches and develops medical technologies for detecting retinal malfunction and deterioration, where he was responsible for all financial functions, and lead financial rounds of equity including M&A activities with strategic partners.
Prior to this position, he served as Controller of GE Healthcare Israel.
Mr. Levy began his career at Deloitte LLP, holds a BA in Accounting and Economics and an LLM degree from Bar Ilan University and is a Certified Public Accountant.